Omalizumab: A Viewpoint by Anthony J. Frew

ISSN： 0012-6667

Source： Drugs, Vol.61, Iss.2, 2001-01, pp. : 261-261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ezetimibe: A Viewpoint by Anthony S. Wierzbicki

By Wierzbicki A.S.

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 1, 2003-01 ,pp. : 77-78

Adis International

Access to resources Recommend Favorite

Atomoxetine: A Viewpoint by J. Elia

By Elia J.

Pediatric Drugs, Vol. 5, Iss. 6, 2003-01 ,pp. : 416-417

Adis International

Access to resources Recommend Favorite

Omalizumab

By Easthope S. Jarvis B.

Drugs, Vol. 61, Iss. 2, 2001-01 ,pp. : 253-260

Adis International

Access to resources Recommend Favorite

Sunitinib: A Viewpoint by Robert J. Motzer

By Motzer Robert J.

Drugs, Vol. 66, Iss. 17, 2006-01 ,pp. : 2267-2268

Adis International

Access to resources Recommend Favorite

Tegafur/Uracil: A Viewpoint by J. Feliu

By Feliu J.

Drugs & Aging, Vol. 18, Iss. 12, 2001-12 ,pp. : 949-950

Adis International

Access to resources Recommend Favorite